Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1016/j.ekir.2024.05.004
10.1016/j.ekir.2024.05.004 · External reference
